Search Results - "Sung Bae Kim"

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management by Jerusalem, Guy, Lancellotti, Patrizio, Kim, Sung-Bae

“…Background Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. For patients with human…”
Get full text

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial by Kato, Ken, Cho, Byoung Chul, Takahashi, Masanobu, Okada, Morihito, Lin, Chen-Yuan, Chin, Keisho, Kadowaki, Shigenori, Ahn, Myung-Ju, Hamamoto, Yasuo, Doki, Yuichiro, Yen, Chueh-Chuan, Kubota, Yutaro, Kim, Sung-Bae, Hsu, Chih-Hung, Holtved, Eva, Xynos, Ioannis, Kodani, Mamoru, Kitagawa, Yuko

“…Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our…”
Get full text

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study by Sun, Jong-Mu, Shen, Lin, Shah, Manish A, Enzinger, Peter, Adenis, Antoine, Doi, Toshihiko, Kojima, Takashi, Metges, Jean-Philippe, Li, Zhigang, Kim, Sung-Bae, Cho, Byoung Chul, Mansoor, Wasat, Li, Shau-Hsuan, Sunpaweravong, Patrapim, Maqueda, Maria Alsina, Goekkurt, Eray, Hara, Hiroki, Antunes, Luis, Fountzilas, Christos, Tsuji, Akihito, Oliden, Victor Castro, Liu, Qi, Shah, Sukrut, Bhagia, Pooja, Kato, Ken

“…First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the…”
Get full text

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial by Krop, Ian E, Dr, Kim, Sung-Bae, Prof, Martin, Antonio Gonzalez, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, MD, Badovinac-Crnjevic, Tanja, MD, Hoersch, Silke, MSc, Smitt, Melanie, MD, Wildiers, Hans, Prof

“…Summary Background In the randomised, parallel assignment, open-label, phase 3 TH3RESA study, progression-free survival was significantly longer with…”
Get full text

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial by Emens, Leisha A, Esteva, Francisco J, Beresford, Mark, Saura, Cristina, De Laurentiis, Michelino, Kim, Sung-Bae, Im, Seock-Ah, Wang, Yifan, Salgado, Roberto, Mani, Aruna, Shah, Jigna, Lambertini, Chiara, Liu, Haiying, de Haas, Sanne L, Patre, Monika, Loi, Sherene

“…HER2-positive metastatic breast cancer is incurable and new treatments are needed. Addition of atezolizumab to trastuzumab emtansine might potentiate…”
Get full text

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial by Hurvitz, Sara A, Hegg, Roberto, Chung, Wei-Pang, Im, Seock-Ah, Jacot, William, Ganju, Vinod, Chiu, Joanne Wing Yan, Xu, Binghe, Hamilton, Erika, Madhusudan, Srinivasan, Iwata, Hiroji, Altintas, Sevilay, Henning, Jan-Willem, Curigliano, Giuseppe, Perez-Garcia, José Manuel, Kim, Sung-Bae, Petry, Vanessa, Huang, Chiun-Sheng, Li, Wei, Frenel, Jean-Sebastien, Antolin, Silvia, Yeo, Winnie, Bianchini, Giampaolo, Loi, Sherene, Tsurutani, Junji, Egorov, Anton, Liu, Yali, Cathcart, Jillian, Ashfaque, Shahid, Cortés, Javier

“…An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast…”
Get full text

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer by Kojima, Takashi, Shah, Manish A, Muro, Kei, Francois, Eric, Adenis, Antoine, Hsu, Chih-Hung, Doi, Toshihiko, Moriwaki, Toshikazu, Kim, Sung-Bae, Lee, Se-Hoon, Bennouna, Jaafar, Kato, Ken, Shen, Lin, Enzinger, Peter, Qin, Shu-Kui, Ferreira, Paula, Chen, Jia, Girotto, Gustavo, de la Fouchardiere, Christelle, Senellart, Helene, Al-Rajabi, Raed, Lordick, Florian, Wang, Ruixue, Suryawanshi, Shailaja, Bhagia, Pooja, Kang, S Peter, Metges, Jean-Philippe

“…Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. In this open-label, phase III…”
Get full text

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer by Modi, Shanu, Jacot, William, Yamashita, Toshinari, Sohn, Joohyuk, Vidal, Maria, Tokunaga, Eriko, Tsurutani, Junji, Ueno, Naoto T., Prat, Aleix, Chae, Yee Soo, Lee, Keun Seok, Niikura, Naoki, Park, Yeon Hee, Xu, Binghe, Wang, Xiaojia, Gil-Gil, Miguel, Li, Wei, Pierga, Jean-Yves, Im, Seock-Ah, Moore, Halle C.F., Rugo, Hope S., Yerushalmi, Rinat, Zagouri, Flora, Gombos, Andrea, Kim, Sung-Bae, Liu, Qiang, Luo, Ting, Saura, Cristina, Schmid, Peter, Sun, Tao, Gambhire, Dhiraj, Yung, Lotus, Wang, Yibin, Singh, Jasmeet, Vitazka, Patrik, Meinhardt, Gerold, Harbeck, Nadia, Cameron, David A.

“…More than half of breast cancers express low levels of HER2. In a phase 3 trial, the antibody–drug conjugate trastuzumab deruxtecan resulted in longer survival…”
Get full text

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer by Schlumberger, Martin, Tahara, Makoto, Wirth, Lori J, Robinson, Bruce, Brose, Marcia S, Elisei, Rossella, Habra, Mouhammed Amir, Newbold, Kate, Shah, Manisha H, Hoff, Ana O, Gianoukakis, Andrew G, Kiyota, Naomi, Taylor, Matthew H, Kim, Sung-Bae, Krzyzanowska, Monika K, Dutcus, Corina E, de las Heras, Begoña, Zhu, Junming, Sherman, Steven I

“…In a phase 3, placebo-controlled study, lenvatinib was associated with a significant increase in progression-free survival (18.3 months vs. 3.6 months). Toxic…”
Get full text

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial by André, Fabrice, Hee Park, Yeon, Kim, Sung-Bae, Takano, Toshimi, Im, Seock-Ah, Borges, Giuliano, Lima, Joao Paulo, Aksoy, Sercan, Gavila Gregori, Joaquin, De Laurentiis, Michelino, Bianchini, Giampaolo, Roylance, Rebecca, Miyoshi, Yasuo, Armstrong, Anne, Sinha, Rajni, Ruiz Borrego, Manuel, Lim, Elgene, Ettl, Johannes, Yerushalmi, Rinat, Zagouri, Flora, Duhoux, Francois P, Fehm, Tanja, Gambhire, Dhiraj, Cathcart, Jillian, Wu, Cai, Chu, Changan, Egorov, Anton, Krop, Ian

“…In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who…”
Get full text

Bioluminescent Imaging Systems for Assay Developments by KIM, Sung-Bae, PAULMURUGAN, Ramasamy

“…Bioluminescence (BL) is an excellent optical readout platform that has great potential to be utilized in various bioassays and molecular imaging. The…”
Get full text

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial by Tolaney, Sara M, Wardley, Andrew M, Zambelli, Stefania, Hilton, John F, Troso-Sandoval, Tiffany A, Ricci, Francesco, Im, Seock-Ah, Kim, Sung-Bae, Johnston, Stephen RD, Chan, Arlene, Goel, Shom, Catron, Kristen, Chapman, Sonya C, Price, Gregory L, Yang, Zhengyu, Gainford, M Corona, André, Fabrice

“…Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The…”
Get full text

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial by Soulières, Denis, Prof, Faivre, Sandrine, Prof, Mesía, Ricard, Prof, Remenár, Éva, Prof, Li, Shau-Hsuan, Prof, Karpenko, Andrey, Prof, Dechaphunkul, Arunee, MD, Ochsenreither, Sebastian, Prof, Kiss, Laura Anna, Prof, Lin, Jin-Ching, Prof, Nagarkar, Raj, Prof, Tamás, László, Prof, Kim, Sung-Bae, Prof, Erfán, Jozsef, Prof, Alyasova, Anna, Prof, Kasper, Stefan, Prof, Barone, Carlo, Prof, Turri, Sabine, MS, Chakravartty, Arunava, PhD, Chol, Marie, PhD, Aimone, Paola, Prof, Hirawat, Samit, Prof, Licitra, Lisa, Prof

“…Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation in squamous cell carcinoma of the head and neck contributes to treatment resistance…”
Get full text

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study by Shen, Lin, Kato, Ken, Kim, Sung-Bae, Ajani, Jaffer A, Zhao, Kuaile, He, Zhiyong, Yu, Xinmin, Shu, Yongqian, Luo, Qi, Wang, Jufeng, Chen, Zhendong, Niu, Zuoxing, Zhang, Longzhen, Yi, Tienan, Sun, Jong-Mu, Chen, Jianhua, Yu, Guohua, Lin, Chen-Yuan, Hara, Hiroki, Bi, Qing, Satoh, Taroh, Pazo-Cid, Roberto, Arkenau, Hendrick-Tobias, Borg, Christophe, Lordick, Florian, Li, Liyun, Ding, Ningning, Tao, Aiyang, Shi, Jingwen, Van Cutsem, Eric

“…Patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) have poor prognosis. For these patients, treatment options are limited after…”
Get full text

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy by Jeong, Jae Ho, Kim, Sung-Bae

“…Although breast cancer has a good prognosis compared with various cancers, metastatic breast cancer has an aggressive disease course and remains incurable…”
Get full text

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial by Krop, Ian E, Dr, Kim, Sung-Bae, Prof, González-Martín, Antonio, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, Prof, Smitt, Melanie, MD, Yu, Ron, PhD, Leung, Abraham C F, MD, Wildiers, Hans, Prof

“…Summary Background Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective…”
Get full text

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer by Kim, Sung‐Bae, Wildiers, Hans, Krop, Ian E., Smitt, Melanie, Yu, Ron, Lysbet de Haas, Sanne, Gonzalez‐Martin, Antonio

“…In the phase III TH3RESA study (NCT01419197), 602 patients with HER2‐positive advanced breast cancer who received prior taxane therapy and ≥2 HER2‐directed…”
Get full text

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study by Swain, Sandra M, Dr, Kim, Sung-Bae, MD, Cortés, Javier, MD, Ro, Jungsil, MD, Semiglazov, Vladimir, MD, Campone, Mario, MD, Ciruelos, Eva, MD, Ferrero, Jean-Marc, MD, Schneeweiss, Andreas, MD, Knott, Adam, PhD, Clark, Emma, MSc, Ross, Graham, FFPM, Benyunes, Mark C, MD, Baselga, José, MD

“…Summary Background CLEOPATRA is a phase 3 study to compare the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and…”
Get full text

Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma by Lim, Won Sub, Roh, Jong‐Lyel, Kim, Sung‐Bae, Choi, Seung‐Ho, Nam, Soon Yuhl, Kim, Sang Yoon

“…Objectives/Hypothesis Poor nutritional status in patients with head and neck squamous cell carcinoma (HNSCC) is associated with tumor progression and survival…”
Get full text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial by Kim, Sung-Bae, Dent, Rebecca, Im, Seock-Ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, Kim, Sung-Bae, Lee, Keun Seok, Im, Seock-Ah, Espié, Marc, Wang, Hwei-Chung, Blau, Sibel, Dent, Rebecca, Tan, Antoinette, Sohn, Joo Hyuk, De Laurentiis, Michelino, Estevez, Laura Garcia, Huang, Chiun-Sheng, Romieu, Gilles, Velez, Michel, Villanueva, Rafael, Conte, Pier Franco, Dakhil, Shaker, Debled, Marc, Martin, Antonio Gonzalez, Hurvitz, Sara, Kim, Jee Hyun, Levy, Christelle, Oliveira, Mafalda, Rovira, Pedro Sanchez, Seo, Jae Hong, Valero, Vicente, Vidal, Gregory, Wong, Andrea, Allison, Mary Ann K, Figlin, Robert, Chan, David, Chen, Shin-Cheh, Chen, Yen-Hsun, Cobleigh, Melody, De Braud, Filippo, Dirix, Luc, Hansen, Vincent, Bessard, Anne Hardy, Iannotti, Nicholas, Isakoff, Steven, Lawler, William, Montaño, Alvaro, Salkini, Mohamad, Seigel, Leonard

“…The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast…”
Get full text